QUEST informs readers of the latest advances in urologic prostate cancer research, especially detection, prevention, and treatment.
The purpose of watchful waiting in prostate cancer is to avoid adverse effects of active treatment in men who are unlikely to experience long-term benefits of radical treatments due to their limited life expectancy. Is watchful waiting an appropriate management…
This study explores the use of active surveillance for patients with low-risk prostate cancer (LRPC) in Northern Italy. Active surveillance is a treatment strategy where patients are closely monitored instead of receiving immediate, aggressive treatment such as surgery or radiation….
In a phase-3 trial called VISION, researchers studied the effects of lutetium-177 [177Lu]Lu-PSMA-617 (vipivotide tetraxetan) in patients with metastatic castration-resistant prostate cancer. This treatment, when added to standard care, improved both radiographic progression-free survival and overall survival. The study also…
This study aimed to find out if prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) can predict cancer progression in patients with low-grade prostate cancer. These patients had been diagnosed with Grade Group (GG) 1 prostate cancer through…
In the context of prostate cancer management, the standard practice of performing bilateral extended pelvic lymph node dissection (PLND) during radical prostatectomy is being questioned with advancements in imaging technology. Magnetic resonance imaging (MRI)-targeted biopsies now provide more accurate staging,…
A recent study led by Burcu F Darst, PhD (University of Washington and Fred Hutchinson Cancer Research Center) investigated the connection between specific genes and the development of aggressive prostate cancer. Gene testing is currently recommended for men who have…
Researchers conducted a meta- analysis of ten genome-wide association studies of more than19,000 cases and 60,000 controls of African ancestry to identify common genetic variants contributing to the risk of prostate cancer in men of African ancestry. They discovered…
Grade group 1 (GG1) prostate cancers, with a Gleason score of 6, are considered low-risk and not likely to lead to death. Because they are generally slow-growing and not aggressive, treatment is often not needed. These cancers rarely spread to…
This study examined the use of PSMA-PET, an advanced imaging technique, and how its use might improve outcomes for patients with recurring prostate cancer. PSMA-PET is more sensitive and specific than older imaging methods like CT scans and bone…
Researchers compared the cardiovascular risks associated with luteinizing hormone-releasing hormone (LHRH) agonists versus gonadotropin-releasing hormone (GnRH) antagonists in prostate cancer patients undergoing androgen deprivation therapy (ADT). Scientists conducted a retrospective analysis using real-world data from more than 45,000 men with…
"*" indicates required fields
